Skip to contentN
Niagen Bioscience, Inc.
N
NAGENiagen Bioscience, Inc. Q3 2020 · 10-Q
Revenue$14.18M$14.18M+17.6% vs Q3 2019 Net Income-$4.22M-$4.22MN/M vs Q3 2019 EPS Diluted-$0.07-$0.07N/M vs Q3 2019 Gross Profit$8,454,000+25.3% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Niagen Bioscience, Inc. · CIK 1386570 · Engraved from SEC EDGAR
Operating Cash Flowderived-$3,845,000N/M Free Cash Flowderived-$3,885,000N/M Margins · derivedGross margin59.6%+3.6 pt vs Q3 2019
Operating margin-29.6%+27.6 pt vs Q3 2019
Net margin-29.7%+30.0 pt vs Q3 2019
ended Sep 30, 2020 · filed Nov 4, 2020 · 35 d after period end